Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 11/2010

01-11-2010 | Breast Oncology

Minimal Disease in the Sentinel Lymph Node: How to Best Measure Sentinel Node Micrometastases to Predict Risk of Additional Non-Sentinel Lymph Node Disease

Authors: Shicha Kumar, MD, Matthew Bramlage, MD, Lindsay M. Jacks, MS, Jessica I. Goldberg, BA, Sujata M. Patil, PhD, Dilip D. Giri, MD, Kimberly J. Van Zee, MS, MD

Published in: Annals of Surgical Oncology | Issue 11/2010

Login to get access

Abstract

Background

Volume of disease in the sentinel lymph node (SLN) is a significant predictor of additional nodal metastasis. This study assesses incidence of residual non-SLN disease in a large cohort of women with minimal SLN metastases and compares three methods of SLN micrometastasis volume measurement to determine which best predicts residual disease on completion axillary lymph node dissection (cALND).

Methods

A total of 505 patients with invasive breast cancer and minimal SLN metastasis (pN1mi or pN0(i+)) underwent cALND and had complete data. All SLNs were evaluated by three measurement methods for volume of metastasis: (1) method of detection (frozen section, routine hematoxylin and eosin, serial hematoxylin and eosin, immunohistochemistry), (2) American Joint Committee on Cancer’s AJCC Cancer Staging Manual, 7th edition, N category, and (3) number of metastatic cells (1–100, 101–999, ≥1000). Multivariable logistic regression models were used to predict the presence of additional non-SLN disease.

Results

A total of 251 patients (50%) had pN0(i+) and 254 patients (50%) had pN1mi disease. Twelve percent of those with pN0(i+) and 20% with pN1mi had additional non-SLN disease. On multivariate analyses including eight variables, only lymphovascular invasion (odds ratio >2.2, P < 0.01) and volume of nodal metastasis as assessed by any method of measurement (method of detection, AJCC, and cell count) were significantly correlated with additional non-SLN disease (P = 0.04, 0.03, and 0.02, respectively). All three models had similar goodness of fit and discrimination (Akaike information criterion = 442, 442, 441; −2log likelihood = 416, 420, 417; concordance index = 0.680, 0.675, 0.676, respectively).

Conclusions

A significant proportion of women with minimal SLN metastases have additional non-SLN disease at cALND. Assessments of SLN volume of disease by three different methods of measurement are equivalent for prediction of additional non-SLN metastases.
Literature
1.
Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol. 1997;15:2345–50.PubMed
2.
Chu KU, Turner RR, Hansen NM, et al. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg. 1999;229:536–41.CrossRefPubMed
3.
Reynolds C, Mick R, Donohue JH, et al. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol. 1999;17:1720–6.PubMed
4.
Teng S, Dupont E, McCann C, et al. Do cytokeratin-positive-only sentinel lymph nodes warrant complete axillary lymph node dissection in patients with invasive breast cancer? Am Surg. 2000;66:574–8.PubMed
5.
Turner RR, Chu KU, Qi K, et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer. 2000;89:574–81.CrossRefPubMed
6.
Abdessalam SF, Zervos EE, Prasad M, et al. Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer. Am J Surg. 2001;182:316–20.CrossRefPubMed
7.
Kamath VJ, Giuliano R, Dauway EL, et al. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch Surg. 2001;136:688–92.CrossRefPubMed
8.
Rahusen FD, Torrenga H, van Diest PJ, et al. Predictive factors for metastatic involvement of nonsentinel nodes in patients with breast cancer. Arch Surg. 2001;136:1059–63.CrossRefPubMed
9.
Viale G, Maiorano E, Mazzarol G, et al. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer. 2001;92:1378–84.CrossRefPubMed
10.
Weiser MR, Montgomery LL, Tan LK, et al. Lymphovascular invasion enhances the prediction of non-sentinel node metastases in breast cancer patients with positive sentinel nodes. Ann Surg Oncol. 2001;8:145–9.CrossRefPubMed
11.
Sachdev U, Murphy K, Derzie A, et al. Predictors of nonsentinel lymph node metastasis in breast cancer patients. Am J Surg. 2002;183:213–7.CrossRefPubMed
12.
Cox CE, Kiluk JV, Riker AI, et al. Significance of sentinel lymph node micrometastases in human breast cancer. J Am Coll Surg. 2008;206:261–8.CrossRefPubMed
13.
Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10:1140–51.CrossRefPubMed
14.
Hwang RF, Krishnamurthy S, Hunt KK, et al. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol. 2003;10:248–54.CrossRefPubMed
15.
Saidi RF, Dudrick PS, Remine SG, Mittal VK. Nonsentinel lymph node status after positive sentinel lymph node biopsy in early breast cancer. Am Surg. 2004;70:101–5.PubMed
16.
Barranger E, Coutant C, Flahault A, et al. An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat. 2005;91:113–9.CrossRefPubMed
17.
Degnim AC, Reynolds C, Pantvaidya G, et al. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg. 2005;190:543–50.CrossRefPubMed
18.
Viale G, Maiorano E, Pruneri G, et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg. 2005;241:319–25.CrossRefPubMed
19.
Pal A, Provenzano E, Duffy SW, Pinder SE, Purushotham AD. A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg. 2008;95:302–9.CrossRefPubMed
20.
Kohrt HE, Olshen RA, Bermas HR et al (2008) New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer. 8:66.CrossRefPubMed
21.
Houvenaeghel G, Nos C, Giard S, et al. A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis. Eur J Surg Oncol. 2009;35:690–5.PubMed
22.
Greene FL, Page DL, Fleming ID, et al. Breast. In: Greene FL, Page DL, Fleming ID, et al, eds. AJCC cancer staging manual, 6th ed. New York: Springer, 2002:221–40.
23.
Wong SL, Edwards MJ, Chao C, et al. Predicting the status of the nonsentinel axillary nodes: a multicenter study. Arch Surg. 2001;136:563–8.CrossRefPubMed
24.
Mignotte H, Treilleux I, Faure C, Nessah K, Bremond A. Axillary lymph-node dissection for positive sentinel nodes in breast cancer patients. Eur J Surg Oncol. 2002;28:623–6.CrossRefPubMed
25.
Jakub JW, Diaz NM, Ebert MD, et al. Completion axillary lymph node dissection minimizes the likelihood of false negatives for patients with invasive breast carcinoma and cytokeratin positive only sentinel lymph nodes. Am J Surg. 2002;184:302–6.CrossRefPubMed
26.
Tan LK, Giri D, Hummer AJ, et al. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol. 2008;26:1803–9.CrossRefPubMed
27.
Meric F, Buchholz TA, Mirza NQ, et al. Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol. 2002;9:543–9.CrossRefPubMed
28.
Roberts CA, Beitsch PD, Litz CE, et al. Interpretive disparity among pathologists in breast sentinel lymph node evaluation. Am J Surg. 2003;186:324–9.CrossRefPubMed
29.
Cserni G, Amendoeira I, Apostolikas N, et al. Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology. J Clin Pathol. 2004;57:695–701.CrossRefPubMed
30.
Cserni G, Bianchi S, Boecker W, et al. Improving the reproducibility of diagnosing micrometastases and isolated tumor cells. Cancer. 2005;103:358–67.CrossRefPubMed
31.
Turner RR, Weaver DL, Cserni G, et al. Nodal stage classification for breast carcinoma: improving interobserver reproducibility through standardized histologic criteria and image-based training. J Clin Oncol. 2008;26:258–63.CrossRefPubMed
32.
Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual, 7th ed. New York: Springer, 2010.
33.
34.
Park J, Fey JV, Naik AM, et al. A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. Ann Surg. 2007;245:462–8.CrossRefPubMed
35.
Bilimoria KY, Bentrem DJ, Hansen NM, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27:2946–53.CrossRefPubMed
36.
Cserni G, Gregori D, Merletti F, et al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg. 2004;91:1245–52.CrossRefPubMed
37.
van Deurzen CH, de Boer M, Monninkhof EM, et al. Non-sentinel lymph node metastases associated with isolated breast cancer cells in the sentinel node. J Natl Cancer Inst. 2008;100:1574–80.CrossRefPubMed
38.
Cody HS 3rd, Borgen PI. State-of-the-art approaches to sentinel node biopsy for breast cancer: study design, patient selection, technique, and quality control at Memorial Sloan-Kettering Cancer Center. Surg Oncol. 1999;8:85–91.CrossRefPubMed
39.
Smidt ML, Kuster DM, van der Wilt GJ, Thunnissen FB, Van Zee KJ, Strobbe LJ. Can the Memorial Sloan-Kettering Cancer Center nomogram predict the likelihood of nonsentinel lymph node metastases in breast cancer patients in the Netherlands? Ann Surg Oncol. 2005;12:1066–72.CrossRefPubMed
40.
Soni NK, Carmalt HL, Gillett DJ, Spillane AJ. Evaluation of a breast cancer nomogram for prediction of non-sentinel lymph node positivity. Eur J Surg Oncol. 2005;31:958–64.CrossRefPubMed
41.
Lambert LA, Ayers GD, Hwang RF, et al. Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol. 2006;13:310–20.CrossRefPubMed
42.
Cripe MH, Beran LC, Liang WC, Sickle-Santanello BJ. The likelihood of additional nodal disease following a positive sentinel lymph node biopsy in breast cancer patients: validation of a nomogram. Am J Surg. 2006;192:484–7.CrossRefPubMed
43.
Alran S, De Rycke Y, Fourchotte V, et al. Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy. Ann Surg Oncol. 2007;14:2195–201.CrossRefPubMed
44.
Cserni G. Comparison of different validation studies on the use of the Memorial-Sloan Kettering Cancer Center nomogram predicting nonsentinel node involvement in sentinel node–positive breast cancer patients. Am J Surg. 2007;194:699–700.CrossRefPubMed
45.
Dauphine CE, Haukoos JS, Vargas MP, et al. Evaluation of three scoring systems predicting non sentinel node metastasis in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2007;14:1014–9.CrossRefPubMed
46.
Ponzone R, Maggiorotto F, Mariani L, et al. Comparison of two models for the prediction of nonsentinel node metastases in breast cancer. Am J Surg. 2007;193:686–92.CrossRefPubMed
47.
Zgajnar J, Perhavec A, Hocevar M, et al. Low performance of the MSKCC nomogram in preoperatively ultrasonically negative axillary lymph node in breast cancer patients. J Surg Oncol. 2007;96:547–53.CrossRefPubMed
48.
Klar M, Jochmann A, Foeldi M, et al. The MSKCC nomogram for prediction the likelihood of non-sentinel node involvement in a German breast cancer population. Breast Cancer Res Treat. 2008;112:523–31.CrossRefPubMed
49.
Poirier E, Sideris L, Dube P, Drolet P, Meterissian SH. Analysis of clinical applicability of the breast cancer nomogram for positive sentinel lymph node: the Canadian experience. Ann Surg Oncol. 2008;15:2562–7.CrossRefPubMed
50.
Unal B, Gur AS, Kayiran O, et al. Models for predicting non-sentinel lymph node positivity in sentinel node positive breast cancer: the importance of scoring system. Int J Clin Pract. 2008;62:1785–91.CrossRefPubMed
51.
Amanti C, Lombardi A, Maggi S, et al. Is complete axillary dissection necessary for all patients with positive findings on sentinel lymph node biopsy? Validation of a breast cancer nomogram for predicting the likelihood of a non-sentinel lymph node. Tumori. 2009;95:153–5.PubMed
52.
Coufal O, Pavlik T, Fabian P, et al. Predicting non-sentinel lymph node status after positive sentinel biopsy in breast cancer: what model performs the best in a Czech population? Pathol Oncol Res. 2009;15:733–40.CrossRefPubMed
53.
Coutant C, Olivier C, Lambaudie E, et al. Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. J Clin Oncol. 2009;27:2800–8.CrossRefPubMed
54.
Ramjeesingh R, Quan ML, Gardner S, Holloway CM. Prediction of involvement of sentinel and nonsentinel lymph nodes in a Canadian population with breast cancer. Can J Surg. 2009;52:23–30.PubMed
55.
van la Parra RF, Ernst MF, Bevilacqua JL, et al. Validation of a nomogram to predict the risk of nonsentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy: validation of the MSKCC breast nomogram. Ann Surg Oncol. 2009;16:1128–35.CrossRef
56.
Dowlatshahi K, Fan M, Bloom KJ, et al. Occult metastases in the sentinel lymph nodes of patients with early stage breast carcinoma: a preliminary study. Cancer. 1999;86:990–6.CrossRefPubMed
57.
Houvenaeghel G, Nos C, Mignotte H, et al. Micrometastases in sentinel lymph node in a multicentric study: predictive factors of nonsentinel lymph node involvement—Groupe des Chirurgiens de la Federation des Centres de Lutte Contre le Cancer. J Clin Oncol. 2006;24:1814–22.CrossRefPubMed
58.
Cody HSI. How do we evaluate sentinel nodes and interpret the findings? Curr Breast Cancer Rep. 2009;1:12–20.CrossRef
59.
Cserni G, Bianchi S, Vezzosi V, et al. Variations in sentinel node isolated tumour cells/micrometastasis and non-sentinel node involvement rates according to different interpretations of the TNM definitions. Eur J Cancer. 2008;44:2185–91.CrossRefPubMed
60.
Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001;93:358–66.CrossRefPubMed
61.
Brennan MF, Kattan MW, Klimstra D, Conlon K. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg. 2004;240:293–8.CrossRefPubMed
62.
Goldstein LJ, Gray R, Badve S, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008;26:4063–71.CrossRefPubMed
63.
Kattan MW, Gonen M, Jarnagin WR, et al. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg. 2008;247:282–7.CrossRefPubMed
64.
Mook S, Schmidt MK, Rutgers EJ, et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol. 2009;10:1070–6.CrossRefPubMed
65.
Specht MC, Kattan MW, Gonen M, Fey J, Van Zee KJ. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol. 2005;12:654–9.CrossRefPubMed
66.
Nos C, Harding-MacKean C, Freneaux P, et al. Prediction of tumour involvement in remaining axillary lymph nodes when the sentinel node in a woman with breast cancer contains metastases. Br J Surg. 2003;90(11):1354–60.CrossRefPubMed
67.
Dabbs DJ, Fung M, Landsittel D, McManus K, Johnson R. Sentinel lymph node micrometastasis as a predictor of axillary tumor burden. Breast J. 2004;10:101–5.CrossRefPubMed
68.
Fleming FJ, Kavanagh D, Crotty TB, et al. Factors affecting metastases to non-sentinel lymph nodes in breast cancer. J Clin Pathol. 2004;57:73–6.CrossRefPubMed
69.
Menes TS, Tartter PI, Mizrachi H, et al. Breast cancer patients with pN0(i+) and pN1(mi) sentinel nodes have high rate of nonsentinel node metastases. J Am Coll Surg. 2005;200:323–7.CrossRefPubMed
70.
Gipponi M, Canavese G, Lionetto R, et al. The role of axillary lymph node dissection in breast cancer patients with sentinel lymph node micrometastases. Eur J Surg Oncol. 2006;32:143–7.CrossRefPubMed
71.
Katz A, Niemierko A, Gage I, et al. Can axillary dissection be avoided in patients with sentinel lymph node metastasis? J Surg Oncol. 2006;93:550–8.CrossRefPubMed
72.
van Rijk MC, Peterse JL, Nieweg OE, et al. Additional axillary metastases and stage migration in breast cancer patients with micrometastases or submicrometastases in sentinel lymph nodes. Cancer. 2006;107:467–71.CrossRefPubMed
73.
Reed J, Rosman M, Verbanac KM, et al. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study. J Am Coll Surg. 2009;208:333–40.CrossRefPubMed
74.
Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106.PubMed
75.
Naik AM, Fey J, Gemignani M, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg. 2004;240:462–8.CrossRefPubMed
76.
Galimberti V. International Breast Cancer Study Group trial of sentinel node biopsy. J Clin Oncol. 2006;24:210–1.CrossRefPubMed
77.
Olson JA Jr, McCall LM, Beitsch P, et al. Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group trials Z0010 and Z0011. J Clin Oncol. 2008;26:3530–5.CrossRefPubMed
78.
Rutgers EJ, Meijnen P, Bonnefoi H. Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group. Breast Cancer Res. 2004;6:165–9.CrossRefPubMed
Metadata
Title
Minimal Disease in the Sentinel Lymph Node: How to Best Measure Sentinel Node Micrometastases to Predict Risk of Additional Non-Sentinel Lymph Node Disease
Authors
Shicha Kumar, MD
Matthew Bramlage, MD
Lindsay M. Jacks, MS
Jessica I. Goldberg, BA
Sujata M. Patil, PhD
Dilip D. Giri, MD
Kimberly J. Van Zee, MS, MD
Publication date
01-11-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 11/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1115-z

Other articles of this Issue 11/2010

Annals of Surgical Oncology 11/2010 Go to the issue

Endocrine Tumors

25-Hydroxyvitamin D Status Does Not Affect Intraoperative Parathyroid Hormone Dynamics in Patients with Primary Hyperparathyroidism

Melanomas

Detection of Melanoma Nodal Metastases; Differences in Detection Between Elderly and Younger Patients Do Not Affect Survival

Breast Oncology

Ductal Carcinoma in Situ of the Breast Treated with Accelerated Partial Breast Irradiation Using Balloon-Based Brachytherapy

Translational Research and Biomarkers

Abnormal Expression of PFDN4 in Colorectal Cancer: A Novel Marker for Prognosis

Colorectal Cancer

Robotic Right Colon Resection: Evaluation of First 50 Consecutive Cases for Malignant Disease

Radiation Oncology

Radiosurgery of Liver Tumors: Value of Robotic Radiosurgical Device to Treat Liver Tumors